

AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.

Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis (EoE) showed that AstraZeneca and Amgen's TEZSPIREÂ (te

Monthly pay dividend equities offer high yields and potential gains, with the top ten broker-estimated MoPay stocks projected to net 27.10%–65.84% by 2027. BCP Investment Corp (BCIC), CION Investment Corp (CION), and Dynex Capital (DX) stand out for both yield and upside, with CION forecasted to deliver a 45.69% net gain. Thirty 'IDEAL' MoPay equities are highlighted for safer dividends, combining positive one-year returns, free-cash-flow yields above dividend yields, and dividends from $1K invested exceeding share price.

March's top-yielding monthly pay (MoPay) equities offer annual dividends from $1K invested exceeding their share price, presenting volatile but potentially lucrative opportunities. Analyst estimates suggest the top 10 MoPay stocks could deliver average net gains of 35.12% by March 2027, with risk/volatility 25% below the market. Stellus Capital Investment (SCM), CION Investment (CION), and PennantPark Floating Rate Capital (PFLT) lead both by yield and price upside, reinforcing the yield-based 'dogcatcher' strategy.

High-yield ETFs provide investors with avenues to compensate for capital losses, if they occur at all.
No recent filings indexed.